PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity.

Sci Adv · 2026 · PMC13155354 · PMID 42102213

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Additional characterization of these endpoint tumors showed a highly significant reduction in the percentage of ductal tumor lesions in EMyc:PARP2 –/– compared with EMyc:PARP2 +/+ mice (8.7 versus 38.7%) ( Fig. 2E ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.